- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03760952
Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling
Study Overview
Status
Detailed Description
The purpose of this screening study is to identify human leukocyte antigen (HLA) molecular subtype positive and tumor antigen target(s) positive patients. No treatment intervention will occur as part of this screening study.
After diagnosis of advanced and/or solid metastatic cancers, patients will be tested for HLA molecular subtype positivity. Patients that are HLA molecular subtype positive are then assessed to determine if their tumor antigen target(s) is positive (biopsy screening). Fresh tumor tissue obtained by a biopsy for this screening study will be required. If the patient is undergoing a surgical procedure directed towards tumor or palliative treatment (e.g., a resection, debulking surgery, etc.) and has consented to the study, then fresh tissue may be collected during the procedure to avoid the patient being subjected to another biopsy.
Tumor antigen targets in fresh tumor samples will be determined by an in vitro diagnostic (IVD) assay. Therefore, any remaining tumor specimens may be used for exploratory biomarker analyses and validation studies for regulatory approval.
Immatics is conducting clinical studies which target patients with advanced and/or metastatic solid cancers. Patients who are HLA subtype phenotype positive and whose tumors express one or more of the tumor antigen targets of interest may be eligible for ongoing clinical studies of adoptive cell therapy (ACT).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Jorge Rivas, MD
- Phone Number: 346-204-5350
- Email: ctgovinquiries@immatics.com
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Oncology Consultants
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed an Informed Consent Form (ICF)
- Patients ≥ 18 years of age
- Patients with confirmed advanced and/or metastatic solid tumors.
For liver cancer patients, the diagnosis must be confirmed
- Pathological diagnosis of liver cancer based on biopsy/resection is required
- For patients without pathological diagnosis, an imaging technique obtained by computed tomography (CT) scan or magnetic resonance imaging (MRI) is needed.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 0-1
- Life expectancy > 6 months
- There is no limitation for prior anti-cancer treatments
- HLA molecular phenotype positive.
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)1.1
- At least one lesion considered accessible for biopsy unless fresh tumor tissue is being collected during a surgical procedure directed towards tumor treatment or palliative therapy or the patient has uterine cancer (including endometrial cancer or uterine carcinosarcoma) or melanoma
- Patient has adequate pulmonary function
- Acceptable organ and marrow function
- Acceptable coagulation status
- Adequate hepatic function
- Acceptable levels of serum creatinine
- For liver cancer patients only, Child-Pugh score of < 6
Exclusion Criteria:
- History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years
- Patients with primary central nervous system (CNS)/brain tumors
- Patients whose tumors have very low expression of tumor antigen targets such as kidney chromophobe, thyroid carcinoma, and prostate adenocarcinoma
- Patients who are pregnant or are breastfeeding
- Patients with serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents
- Patients with prior stem cell transplantation or solid organ transplantation
- Any condition contraindicating leukapheresis
- Patients with any of the following cardiac conditions: uncontrolled hypertension despite optimal therapy, uncontrolled angina, ventricular arrhythmias, congestive heart failure, baseline left ventricular ejection fraction ≤ 50%, prior or current cardiomyopathy, atrial fibrillation with heart rate > 100 bpm, unstable ischemic heart disease
- Patients with active diverticulitis, intra-abdominal abscess, or GI obstruction
- Patients with active pneumonitis
- Patients with active (uncontrolled/untreated) brain metastases NOTE: Patients with a history of brain metastases may be eligible, if an imaging scan with contrast enhancement not older than 4 weeks is able to exclude the existence of currently active brain metastasis.
- History of hypersensitivity on fludarabine (FLU), cyclophosphamide (CY), or interleukin (IL)-2
- History of current immunodeficiency disease or prior treatment compromising immune function at the discretion of the investigator.
- Patients with Grade 3 or Grade 4 immune-related toxicities related to checkpoint inhibitors or patients requiring corticosteroid treatment (≥ 10 mg/day prednisone or equivalent dose).
- Patients with bleeding diathesis or coagulopathy
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with patient's safety
- HIV infection, active hepatitis B or C infection. History of treated hepatitis B or C is permitted if the viral load is undetectable per qPCR and/or nucleic acid testing
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of patients with protocol-specified HLA subtype
Time Frame: 3 years
|
3 years
|
Frequency of patients with expression of analyzed tumor antigen targets
Time Frame: 3 years
|
3 years
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of antigen target expression in solid tumors
Time Frame: 3 years
|
3 years
|
Comparison of antigen target expression in fresh and FFPE tumor samples
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Cedrik Britten, M.D., Immatics US
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMA-SCREENING
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong